VALN
Valneva SE
Price Chart
Latest Quote
$5.00
-0.08 (-1.57%)
Current Price
| Previous Close | $5.08 |
| Open | $4.99 |
| Day High | $5.05 |
| Day Low | $4.96 |
| Volume | 50,611 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 102.12M |
| Total Debt | $239.79M |
| Cash Equivalents | $120.48M |
| Revenue | $178.93M |
| Net Income | $-157.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $510.60M |
| EPS (TTM) | $-1.82 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $556.83M |
| Sales | $178.93M |
| Income | $-157.99M |
| Book/sh | $0.98 |
| Cash/sh | $1.03 |
| Employees | 674 |
Financial Ratios
| Quick Ratio | 1.23 |
| Current Ratio | 2.14 |
| Debt/Eq | 273.15 |
Returns & Margins
| ROA | -14.54% |
| ROE | -109.57% |
| Gross Margin | -25.27% |
| Operating Margin | -76.67% |
| Profit Margin | -88.30% |
Ownership
| Institutional Ownership | 3.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 4.81 |
| P/S | 3.27 |
| P/B | 5.09 |
Analyst Data
| Recommendation | none |
| Target Price | $12.20 |
Technical Indicators
| SMA20 | $5.22 |
| SMA50 | $5.52 |
| SMA200 | $8.08 |
| RSI | 43.58 |
| ATR | 0.2206 |
| Shares Float | 73.88M |
| Short Float | 0.18% |
| Short Ratio | 7.57 |
| Volatility | 1.41 |
| Rel Volume | 1.69 |
Performance History
| Week | -0.99% |
| Month | -6.72% |
| Quarter | -16.25% |
| 6 Months | -51.78% |
| YTD | -44.17% |
| Year | -22.96% |
| 3 Years | -65.92% |
| 5 Years | -81.46% |
| 10 Years | -81.07% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $5.00 | 50,611 |
| 2026-07-16 | $5.08 | 78,500 |
| 2026-07-15 | $5.12 | 71,700 |
| 2026-07-14 | $5.11 | 60,800 |
| 2026-07-13 | $5.26 | 18,100 |
| 2026-07-10 | $5.05 | 16,100 |
| 2026-07-09 | $5.30 | 9,700 |
| 2026-07-08 | $5.31 | 12,800 |
| 2026-07-07 | $5.26 | 26,600 |
| 2026-07-06 | $5.40 | 20,700 |
| 2026-07-02 | $5.22 | 19,000 |
| 2026-07-01 | $5.09 | 21,000 |
| 2026-06-30 | $5.23 | 32,900 |
| 2026-06-29 | $5.17 | 36,800 |
| 2026-06-26 | $5.19 | 27,500 |
| 2026-06-25 | $5.21 | 52,100 |
| 2026-06-24 | $5.23 | 7,000 |
| 2026-06-23 | $5.40 | 16,600 |
| 2026-06-22 | $5.35 | 7,400 |
| 2026-06-18 | $5.38 | 13,000 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
đ° Latest News
Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...
GuruFocus.com âĸ 2026-05-13T23:00:18ZValneva Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T19:10:56Z
Transcript: Valneva Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T15:51:43Z
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13
Insider Monkey âĸ 2026-04-20T00:10:19Z
Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data
Insider Monkey âĸ 2026-04-07T14:32:47Z
Will Pfizerâs Lyme disease gamble pay off or set the space back?
Pharma Voice âĸ 2026-04-01T08:00:00Z
Pfizer (PFE) â Among the 15 Large Cap Stocks with Highest Dividends
Insider Monkey âĸ 2026-03-30T06:08:57Z
Should Pfizerâs (PFE) New Lyme Vaccine and Oncology Wins Reshape Its PostâCOVID Pipeline Story?
Simply Wall St. âĸ 2026-03-27T13:07:14Z
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
Insider Monkey âĸ 2026-03-27T01:15:14Z
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
Zacks âĸ 2026-03-24T16:12:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $122,879,905 | $113,015,242 | $115,695,595 | $372,108,001 |
| Cost Of Revenue | $122,879,905 | $113,015,242 | $115,695,595 | $372,108,001 |
| Total Revenue | $200,318,823 | $194,492,468 | $176,295,429 | $414,385,781 |
| Operating Revenue | $200,318,823 | $194,492,468 | $176,295,429 | $414,385,781 |
| Expenses | ||||
| Interest Expense | $48,053,671 | $27,507,739 | $26,751,918 | $21,853,421 |
| Total Expenses | $293,943,082 | $283,687,320 | $270,471,356 | $544,495,872 |
| Other Income Expense | $7,758,917 | $100,821,185 | $6,420,460 | $-14,425,965 |
| Net Non Operating Interest Income Expense | $-45,021,213 | $-24,798,713 | $-25,364,145 | $-21,555,222 |
| Total Other Finance Cost | $-964,560 | - | - | - |
| Interest Expense Non Operating | $48,053,671 | $27,507,739 | $26,751,918 | $21,853,421 |
| Operating Expense | $171,063,178 | $170,672,078 | $154,775,761 | $172,387,871 |
| Other Operating Expenses | $-12,850,096 | $-23,839,887 | $-25,198,988 | $-13,991,282 |
| Selling And Marketing Expense | $42,844,358 | $60,048,164 | $55,914,663 | $26,962,952 |
| General And Administrative Expense | $42,805,363 | $49,030,847 | $54,821,648 | $39,079,019 |
| Other Non Operating Income Expenses | - | $104,178,221 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Net Interest Income | $-45,021,213 | $-24,798,713 | $-25,364,145 | $-21,555,222 |
| Interest Income | $2,067,897 | $2,709,026 | $1,387,774 | $298,199 |
| Normalized Income | $-137,935,242 | $-11,528,557 | $-121,146,335 | $-150,046,441 |
| Net Income From Continuing And Discontinued Operation | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Total Operating Income As Reported | $-94,116,288 | $15,288,449 | $-94,147,255 | $-130,110,091 |
| Net Income Common Stockholders | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Net Income | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Net Income Including Noncontrolling Interests | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Net Income Continuous Operations | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Pretax Income | $-130,885,409 | $-13,173,528 | $-113,119,612 | $-166,091,278 |
| Special Income Charges | $-494,323 | $305,081 | $27,526 | $-80,284 |
| Interest Income Non Operating | $2,067,897 | $2,709,026 | $1,387,774 | $298,199 |
| Operating Income | $-93,624,259 | $-89,194,853 | $-94,175,928 | $-130,110,091 |
| Gross Profit | $77,438,918 | $81,477,225 | $60,599,833 | $42,277,780 |
| Earnings From Equity Interest | - | $0 | $0 | $10,322 |
| Per Share | ||||
| Diluted EPS | $-1.56 | $-0.18 | $-1.67 | $-2.84 |
| Basic EPS | $-1.56 | $-0.18 | $-1.67 | $-2.84 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,939,729 | $-839,259 | $1,605,115 | $-153,120 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-65,645,136 | $40,154,830 | $-72,620,706 | $-105,674,952 |
| Total Unusual Items | $7,758,917 | $-3,357,036 | $6,420,460 | $-14,436,287 |
| Total Unusual Items Excluding Goodwill | $7,758,917 | $-3,357,036 | $6,420,460 | $-14,436,287 |
| Reconciled Depreciation | $24,945,519 | $22,463,583 | $20,167,448 | $24,126,618 |
| EBITDA (Bullshit earnings) | $-57,886,220 | $36,797,794 | $-66,200,245 | $-120,111,239 |
| EBIT | $-82,831,738 | $14,334,211 | $-86,367,694 | $-144,237,856 |
| Diluted Average Shares | $96,444,114 | $83,556,521 | $79,678,760 | $66,261,938 |
| Basic Average Shares | $96,444,114 | $83,556,521 | $79,678,760 | $66,261,938 |
| Diluted NI Availto Com Stockholders | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Tax Provision | $1,230,646 | $872,806 | $3,211,377 | $-1,761,670 |
| Gain On Sale Of Ppe | $-495,470 | $-510,380 | $-24,085 | $-43,583 |
| Other Special Charges | $-1,147 | $-815,460 | $-51,611 | $36,701 |
| Gain On Sale Of Security | $8,253,239 | $-3,662,117 | $6,392,934 | $-14,436,287 |
| Other Taxes | $427,801 | $396,834 | $544,787 | $248,882 |
| Research And Development | $97,835,751 | $85,036,119 | $68,693,650 | $120,337,182 |
| Selling General And Administration | $85,649,722 | $109,079,012 | $110,736,312 | $66,041,970 |
| Other Gand A | $42,805,363 | $49,030,847 | $54,821,648 | $39,079,019 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $96,134,868 | $178,912,701 | $117,765,787 | $219,160,432 |
| Total Assets | $457,433,145 | $573,496,901 | $527,654,493 | $712,632,109 |
| Total Non Current Assets | $202,197,479 | $230,553,939 | $226,216,286 | $225,582,039 |
| Other Non Current Assets | $8,706,273 | $9,222,387 | $9,736,207 | $9,518,292 |
| Non Current Deferred Assets | $9,549,259 | $11,016,170 | $7,560,499 | $6,465,190 |
| Non Current Deferred Taxes Assets | $9,549,259 | $11,016,170 | $7,560,499 | $6,465,190 |
| Goodwill And Other Intangible Assets | $25,631,377 | $28,970,062 | $29,323,314 | $32,929,232 |
| Other Intangible Assets | $25,631,377 | $28,970,062 | $29,323,314 | $32,929,232 |
| Current Assets | $255,236,813 | $342,942,963 | $301,437,060 | $487,051,217 |
| Other Current Assets | $39,965,588 | $48,026,145 | $58,072,021 | $84,962,716 |
| Inventory | $57,612,106 | $61,547,189 | $50,998,963 | $40,261,494 |
| Receivables | $31,899,297 | $40,377,333 | $47,763,500 | $27,426,308 |
| Other Receivables | $91,754 | $86,019 | - | - |
| Accounts Receivable | $31,807,543 | $40,291,314 | $47,763,500 | $27,426,308 |
| Allowance For Doubtful Accounts Receivable | $-59,640 | $-59,640 | $-79,138 | $-96,341 |
| Gross Accounts Receivable | $31,867,183 | $40,350,954 | $47,842,638 | $27,522,649 |
| Cash Cash Equivalents And Short Term Investments | $125,759,822 | $192,992,296 | $144,602,577 | $328,629,396 |
| Cash And Cash Equivalents | $125,759,822 | $192,992,296 | $144,602,577 | $328,629,396 |
| Cash Financial | $125,759,822 | $192,992,296 | $144,603,724 | $328,630,543 |
| Cash Equivalents | - | $0 | $-1,147 | $-1,147 |
| Assets Held For Sale Current | - | - | $0 | $2,447,528 |
| Restricted Cash | - | - | $0 | $3,323,775 |
| Debt | ||||
| Net Debt | $79,729,319 | $21,909,620 | $58,226,855 | - |
| Total Debt | $237,696,959 | $248,093,792 | $239,495,330 | $174,768,877 |
| Long Term Debt And Capital Lease Obligation | $214,019,934 | $221,301,732 | $185,638,242 | $132,343,145 |
| Long Term Debt | $184,953,531 | $190,986,332 | $152,274,328 | $100,042,426 |
| Current Debt And Capital Lease Obligation | $23,677,025 | $26,792,061 | $53,857,088 | $42,425,733 |
| Current Debt | $20,535,610 | $23,915,584 | $50,555,104 | $13,281,338 |
| Other Current Borrowings | $20,535,610 | $23,915,584 | $50,555,104 | $13,281,338 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $335,666,900 | $365,614,138 | $380,565,393 | $460,542,446 |
| Total Non Current Liabilities Net Minority Interest | $228,620,231 | $234,201,146 | $198,362,177 | $142,394,755 |
| Other Non Current Liabilities | $280,995 | $55,052 | $90,607 | $131,896 |
| Non Current Deferred Liabilities | $5,056,772 | $4,773,483 | $4,172,496 | $795,963 |
| Non Current Deferred Taxes Liabilities | $5,056,772 | $4,773,483 | $4,172,496 | $795,963 |
| Current Liabilities | $107,046,669 | $131,412,993 | $182,203,216 | $318,147,691 |
| Other Current Liabilities | $6,524,830 | $5,908,934 | $678,977 | $6,334,441 |
| Current Deferred Liabilities | $495,470 | $3,452,230 | $6,534,006 | $10,793,668 |
| Payables And Accrued Expenses | $36,075,234 | $50,021,786 | $57,723,357 | $53,885,761 |
| Payables | $18,336,963 | $23,776,807 | $27,055,852 | $22,934,967 |
| Total Tax Payable | $7,929,808 | $9,280,880 | $6,911,342 | $6,298,887 |
| Income Tax Payable | $1,147 | $1,997,935 | $724,854 | $610,162 |
| Accounts Payable | $10,407,156 | $14,495,927 | $20,144,510 | $16,636,080 |
| Other Payable | - | - | - | $5,688,725 |
| Equity | ||||
| Common Stock Equity | $121,766,245 | $207,882,763 | $147,089,101 | $252,089,663 |
| Total Equity Gross Minority Interest | $121,766,245 | $207,882,763 | $147,089,101 | $252,089,663 |
| Stockholders Equity | $121,766,245 | $207,882,763 | $147,089,101 | $252,089,663 |
| Other Equity Interest | $49,572,194 | $38,647,777 | $27,872,460 | $20,225,941 |
| Gains Losses Not Affecting Retained Earnings | $46,725,537 | $46,051,148 | $47,519,206 | $43,883,468 |
| Other Equity Adjustments | $46,725,537 | $46,051,148 | $47,519,206 | $43,883,468 |
| Retained Earnings | $-778,896,582 | $-646,781,674 | $-632,735,340 | $-516,404,351 |
| Long Term Equity Investment | - | - | - | $0 |
| Other | ||||
| Treasury Shares Number | $142,587 | $142,587 | $142,587 | $142,587 |
| Ordinary Shares Number | $198,893,686 | $186,256,664 | $159,178,582 | $158,696,488 |
| Share Issued | $199,036,274 | $186,399,251 | $159,321,169 | $158,839,075 |
| Tangible Book Value | $96,134,868 | $178,912,701 | $117,765,787 | $219,160,432 |
| Invested Capital | $327,255,385 | $422,784,679 | $349,918,533 | $365,413,427 |
| Working Capital | $148,190,144 | $211,529,970 | $119,233,845 | $168,903,527 |
| Capital Lease Obligations | $32,207,819 | $33,191,876 | $36,665,898 | $61,445,114 |
| Total Capitalization | $306,719,776 | $398,869,095 | $299,363,428 | $352,132,089 |
| Treasury Stock | $739,764 | $739,764 | $739,764 | $739,764 |
| Additional Paid In Capital | $775,249,375 | $742,745,651 | $681,274,158 | $681,320,035 |
| Capital Stock | $29,855,485 | $27,959,626 | $23,898,380 | $23,804,333 |
| Common Stock | $29,855,485 | $27,959,626 | $23,898,380 | $23,804,333 |
| Long Term Capital Lease Obligation | $29,066,404 | $30,315,400 | $33,363,914 | $32,300,719 |
| Long Term Provisions | $9,262,529 | $8,070,879 | $8,460,832 | $9,123,752 |
| Current Deferred Revenue | $495,470 | $3,452,230 | $6,534,006 | $10,793,668 |
| Current Capital Lease Obligation | $3,141,415 | $2,876,476 | $3,301,984 | $29,144,394 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,499,368 | $15,032,686 | $12,403,944 | $12,361,508 |
| Current Provisions | $25,774,742 | $30,205,296 | $51,005,844 | $192,346,580 |
| Current Accrued Expenses | $17,738,271 | $26,244,980 | $30,667,505 | $30,950,794 |
| Net PPE | $158,310,570 | $181,345,319 | $179,596,265 | $176,669,325 |
| Accumulated Depreciation | $-126,037,377 | $-109,148,974 | - | $-77,013,411 |
| Gross PPE | $284,347,946 | $181,345,319 | $179,596,265 | $176,669,325 |
| Leases | $20,865,923 | $21,713,497 | $23,100,124 | $47,442,362 |
| Construction In Progress | $1,183,622 | $4,034,866 | - | $1,815,575 |
| Other Properties | $87,457,268 | $159,631,822 | $156,496,142 | $129,226,962 |
| Machinery Furniture Equipment | $5,774,744 | $5,796,536 | - | $6,187,636 |
| Land And Improvements | $169,066,389 | $173,223,976 | - | $110,709,932 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-50,994,375 | $-40,727,143 | $-52,300,717 | $-207,438,905 |
| Finished Goods | $23,799,745 | $27,818,554 | $19,031,997 | $17,549,029 |
| Work In Process | $55,161,137 | $42,243,372 | $43,690,786 | $130,998,954 |
| Raw Materials | $29,645,598 | $32,212,406 | $40,576,897 | $99,153,562 |
| Employee Benefits | - | - | - | $1,513,935 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Investments And Advances | - | - | - | $0 |
| Investmentsin Associatesat Cost | - | - | - | $0 |
| Other Inventories | - | - | - | $-1,147 |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-65,804,558 | $-95,953,655 | $-248,945,954 | $-315,018,892 |
| Operating Activities | ||||
| Operating Cash Flow | $-60,665,208 | $-77,093,695 | $-232,531,230 | $-281,388,892 |
| Cash Flow From Continuing Operating Activities | $-60,666,355 | $-77,094,842 | $-232,532,376 | $-281,388,892 |
| Operating Gains Losses | $1,145,773 | $-106,311,493 | $-1,251,290 | $-26,269,065 |
| Investing Activities | ||||
| Capital Expenditure | $-5,139,350 | $-18,859,959 | $-16,414,725 | $-33,630,000 |
| Investing Cash Flow | $-1,960,087 | $88,216,529 | $-23,609,356 | $-33,322,625 |
| Cash Flow From Continuing Investing Activities | $-1,960,087 | $88,216,529 | $-23,608,210 | $-33,322,625 |
| Net Other Investing Changes | - | $104,178,221 | $3,850,212 | - |
| Financing Activities | ||||
| Financing Cash Flow | $-712,238 | $35,189,812 | $72,348,886 | $246,720,929 |
| Cash Flow From Continuing Financing Activities | $-713,384 | $35,190,959 | $72,347,739 | $246,720,929 |
| Net Other Financing Charges | $1,147 | $-1,147 | $1,147 | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $34,411,053 | $65,533,885 | $-275,261 | $217,727,928 |
| Dividend Received Cfo | - | $0 | $0 | $0 |
| Repurchase Of Capital Stock | - | - | $-275,261 | - |
| Issuance Of Capital Stock | - | - | $0 | $217,727,928 |
| Common Stock Issuance | - | - | $0 | $217,727,928 |
| Other | ||||
| Repayment Of Debt | $-199,954,103 | $-7,440,073 | $-5,991,512 | $-5,552,242 |
| Issuance Of Debt | $200,024,065 | - | $93,027,861 | $45,109,526 |
| End Cash Position | $125,759,822 | $192,993,443 | $144,603,724 | $328,629,396 |
| Beginning Cash Position | $192,993,443 | $144,603,724 | $328,629,396 | $397,570,781 |
| Effect Of Exchange Rate Changes | $-3,896,089 | $2,077,073 | $-233,972 | $-949,650 |
| Changes In Cash | $-63,337,532 | $46,312,646 | $-183,791,700 | $-67,991,735 |
| Interest Paid Cff | $-35,194,399 | $-22,902,853 | $-14,413,349 | $-10,564,284 |
| Net Issuance Payments Of Debt | $69,962 | $-7,440,073 | $87,036,348 | $39,557,285 |
| Net Long Term Debt Issuance | $69,962 | $-7,440,073 | $87,036,348 | $39,557,285 |
| Long Term Debt Payments | $-199,954,103 | $-7,440,073 | $-5,991,512 | $-5,552,242 |
| Long Term Debt Issuance | $200,024,065 | - | $93,027,861 | $45,109,526 |
| Interest Received Cfi | $2,067,897 | $2,709,026 | $1,387,774 | $298,199 |
| Net Investment Purchase And Sale | $964,560 | $0 | $0 | - |
| Sale Of Investment | $964,560 | $0 | $0 | - |
| Net Business Purchase And Sale | $0 | $0 | $-12,559,925 | $0 |
| Purchase Of Business | $0 | $0 | $-12,559,925 | $0 |
| Net Intangibles Purchase And Sale | $-69,962 | $-2,957,908 | $-92,901 | $-87,166 |
| Purchase Of Intangibles | $-69,962 | $-2,957,908 | $-92,901 | $-87,166 |
| Net PPE Purchase And Sale | $-4,922,582 | $-15,712,809 | $-16,194,516 | $-33,533,659 |
| Sale Of PPE | $146,806 | $189,242 | $127,308 | $9,175 |
| Purchase Of PPE | $-5,069,388 | $-15,902,051 | $-16,321,824 | $-33,542,834 |
| Taxes Refund Paid | $-2,526,666 | $-1,771,992 | $-1,417,594 | $-176,626 |
| Change In Working Capital | $-169,744 | $-13,273,310 | $-166,376,861 | $-167,428,587 |
| Change In Other Working Capital | $-2,981,993 | $-3,203,349 | $-3,980,961 | $-137,451,528 |
| Change In Other Current Liabilities | $-9,057,230 | $-16,988,185 | $-128,435,587 | $-137,274,903 |
| Change In Other Current Assets | $511,526 | $514,967 | $-220,209 | $12,594,333 |
| Change In Payables And Accrued Expense | $-5,109,530 | $-3,808,923 | $-19,954,121 | $-16,117,672 |
| Change In Payable | $-5,109,530 | $-3,808,923 | $-19,954,121 | $-16,117,672 |
| Change In Inventory | $1,183,622 | $-7,802,499 | $-10,511,525 | $96,598,224 |
| Change In Receivables | $15,283,861 | $18,014,679 | $-3,274,458 | $14,222,960 |
| Other Non Cash Items | $34,865,233 | $25,826,354 | $24,443,168 | $37,713,037 |
| Stock Based Compensation | $10,933,592 | $9,146,690 | $5,861,910 | $-9,927,743 |
| Asset Impairment Charge | $1,026,494 | $0 | $-838,399 | $26,664,752 |
| Deferred Tax | $1,230,646 | $872,806 | $3,211,377 | $-1,761,670 |
| Deferred Income Tax | $1,230,646 | $872,806 | $3,211,377 | $-1,761,670 |
| Depreciation Amortization Depletion | $24,945,519 | $22,463,583 | $20,167,448 | $24,126,618 |
| Depreciation And Amortization | $24,945,519 | $22,463,583 | $20,167,448 | $24,126,618 |
| Pension And Employee Benefit Expense | $1,614,864 | $-1,828,191 | $-1,902,741 | $-26,302,326 |
| Gain Loss On Investment Securities | $-964,560 | - | - | - |
| Gain Loss On Sale Of PPE | $495,470 | $-305,081 | $-13,763 | $43,583 |
| Net Income From Continuing Operations | $-132,116,055 | $-14,046,334 | $-116,330,989 | $-164,329,608 |
| Earnings Losses From Equity Investments | - | $0 | $0 | $-10,322 |
| Common Stock Payments | - | - | $-275,261 | - |
| Other Cash Adjustment Outside Changein Cash | - | - | - | $3,323,775 |
| Sale Of Intangibles | - | - | - | $0 |
Fetched: 2026-07-16